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Abstract
Background: The tumor suppressor pRb plays a key role regulating cell cycle arrest, and disturbances in the RB1
gene have been reported in different cancer forms. However, the literature reports contradictory findings with
respect to a pro - versus anti - apoptotic role of pRb, and the consequence of alterations in RB1 to chemotherapy
sensitivity remains unclear. This study is part of a project investigating alterations in pivotal genes as predictive
factors to chemotherapy sensitivity in breast cancer.
Results: Analyzing 73 locally advanced (stage III) breast cancers, we identified two somatic and one germline
single nucleotide changes, each leading to amino acid substitution in the pRb protein (Leu607Ile, Arg698Trp, and
Arg621Cys, respectively). This is the first study reporting point mutations affecting RB1 in breast cancer tissue. In
addition, MLPA analysis revealed two large multiexon deletions (exons 13 to 27 and exons 21 to 23) with the
exons 21-23 deletion occurring in the tumor also harboring the Leu607Ile mutation. Interestingly, Leu607Ile and
Arg621Cys point mutations both localize to the spacer region of the pRb protein, a region previously shown to
harbor somatic and germline mutations. Multiple sequence alignment across species indicates the spacer to be
evolutionary conserved. All three RB1 point mutations encoded nuclear proteins with impaired ability to induce
apoptosis compared to wild-type pRb in vitro. Notably, three out of four tumors harboring RB1 mutations displayed
primary resistance to treatment with either 5-FU/mitomycin or doxorubicin while only 14 out of 64 tumors without
mutations were resistant (p = 0.046).
Conclusions: Although rare, our findings suggest RB1 mutations to be of pathological importance potentially
affecting sensitivity to mitomycin/anthracycline treatment in breast cancer.
Background
The retinoblastoma gene (RB1) is a tumor suppressor
gene. pRb, the protein coded for by the RB1 gene, plays
a pivotal role in cell cycle regulation, promoting G1/S
arrest and growth restriction through inhibition of the
E2F transcription factors [1]. Germline mutations affect-
ing the RB1 gene are strongly associated with retinoblas-
toma development in children, and recent evidence has
revealed an increased risk of different malignancies,
including breast cancers, among patients cured from
hereditary retinoblastoma [2].
Somatic alterations of the RB1 gene have been
detected in different malignancies [3-5]. Previous studies
have reported allelic imbalance (AI), loss of pRb protein
expression [3], hypermethylation of the RB1 promoter
[6] and, in some rare cases, large intragenic deletions [7]
in the RB1 gene in primary breast cancer. However,
point mutations (1163T>C and 1544C>T) have, so far,
only been detected in a single breast cancer cell line
(BT20) [8]. To the best of our knowledge, no point
mutations have previously been reported in biopsies
from breast carcinomas.
While the cellular functions of pRb are well character-
ized, the effect of disturbances in the RB1 gene on
tumor growth and response to systemic therapy in
breast cancer is incompletely understood. Lack of pRb
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locus have been related to triple negative (TNBC) or
basal cell-like breast cancer [9,10]. Absence of pRb
expression has been linked to poor prognosis in breast
cancer patients receiving adjuvant endocrine therapy
[11,12]. In contrast, loss of expression has been asso-
ciated with good prognosis in patients receiving che-
motherapy [10,12]. However, these findings may not be
interpreted as direct evidence that alterations in RB1
predict chemosensitivity [13]. Breast cancer patients are
selected for systemic treatment options based on tumor
characteristics like histological grading, estrogen recep-
tor expression, and Her-2 status, thus, the patient
cohorts referred to above may differ with respect to key
biological parameters. Experimental studies have pro-
vided contradictory results, revealing loss of pRb func-
tion to enhance [11,14-17] as well as to reduce [18,19]
cell death and sensitivity to chemotherapeutic agents.
In the current study, we analyzed 73 breast cancers
undergoing pre-surgical treatment with doxorubicin or
mitomycin with 5-FU for genetic and epigenetic changes
in the RB1 gene. We report for the first time point
mutations affecting RB1 in breast cancer tissue. Each
mutation lead to amino acid substitution (Leu607Ile,
Arg698Trp, and Arg621Cys) in pRb. The mutated pRb
variants were all located to the nuclear compartment
and expressed reduced apoptotic capacity compared to
wild-type pRb. Furthermore, MLPA unveiled two large
multiexon deletions (exons 13 to 27 and exons 21 to
23). Most interesting, three out of four tumors harbor-
ing RB1 mutations expressed resistance to chemother-
apy. Our data provide the first indication that RB1
might be a candidate gene involved in drug resistance.
Results
Sequencing the RB1 coding exons
cDNA generated from 73 locally advanced breast cancer
samples obtained prior to chemotherapy was analyzed by
PCR and DNA sequencing for RB1 mutations. Three
tumors were found to harbor a single nucleotide change
each, all resulting in amino acid substitutions (Table 1).
Each mutation was located within the pocket domain of
pRb (Figure 1). Two of the mutations were located in exon
19: C1819A (Leu607Ile) and C1861T (Arg621Cys), while
the third was located in exon 20: A2092T (Arg698Trp)
(nucleotide numbering according to GeneBank sequence
L11910 with the A of ATG = number one). Each mutation
was verified by amplification and sequencing of genomic
DNA from the corresponding tumor.
To evaluate whether the mutations were somatic or
germline, DNA from corresponding lymphocytes were
analyzed. One of these nucleotide changes, C1861T
(Arg621Cys), was detected in white blood cells from the
affected patient. This patient revealed no family history
suggesting hereditary retinoblastoma. Thus, to evaluate
whether the Arg621Cys alteration was a common poly-
morphism, we sequenced DNA from 231 healthy indivi-
duals. None of these samples harbored the C1861T
nucleotide substitution, arguing against the hypothesis
that C1861T could be a polymorphism occurring among
>1% of the population (p < 0.10).
Promoter analysis
In order to explore the occurrence of promoter aberra-
tions as a possible cause for RB1 inactivation, 71 tumors
were analyzed for RB1 promoter hypermethylation using
methylation specific PCR, and 45 tumors were examined
for mutations of the RB1 promoter by sequencing. No
hypermethylation (Figure2 )o rm u t a t i o n so ft h eRB1
promoter were detected.
Analysing for large exon deletions with use of MLPA
Multiplex ligation-dependent probe amplification (MLPA)
analysis was performed on tumor DNA from 71 of the
Table 1 RB1 alterations observed among patients
included in the study
Patient
1 Alterations in RB1 Response
4
Large rearrangements
2 Point Mutations
3
Dox19 AI WT PD
FUMI 12 AI WT PD
Dox 95 Del exon 13-27 WT PD
FUMI 07 Del exon 21-23 Leu607Ile PD
Dox 48 Duplication WT PD
Dox 65 WT Arg621Cys (G.l) PD
FUMI 39 Duplication WT SD
Dox 04 AI WT SD
Dox 32 AI WT SD
Dox 74 AI WT SD
Dox 83 AI WT SD
FUMI 25 AI WT SD
FUMI 26 AI WT SD
FUMI 27 AI WT SD
FUMI 44 AI WT SD
Dox 15 AI WT PR
Dox 109 AI WT PR
FUMI 15 AI WT PR
FUMI 23 AI WT PR
FUMI 29 AI WT PR
FUMI 37 AI WT PR
Dox 111 AI Arg698Trp PR
Dox 39 Duplication WT PR
FUMI 30 AI WT NE
1 Dox “X”, patients treated with doxorubicin; FUMI “X”, patients treated with
FUMI.
2AI, allelic imbalance; Del, deletion; WT, wild-type.
3G.l, germline.
4 PD,
progressive disease; SD, stable disease; PR, partial response; NE, not evaluable.
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For the remaining two samples, genomic DNA was not
available. Two individual samples harbored one large mul-
tiexon deletion each (exons 13 to 27 and exons 21 to 23),
the exons 21-23 deletion occurring in the tumor also har-
boring the Leu607Ile point mutation (Table 1).
Allelic imbalance
MLPA further revealed the RB1 gene to be duplicated in
three of the samples (4%), and 18 of the tumors (25%)
harbored a reduced copy number at the RB1 locus
(Table 1).
In order to confirm the findings obtained by MLPA,
traditional LOH analysis with VNTR/microsatellites was
performed for all patients from whom white blood cell
DNA was available (n = 43). Allelic imbalance at 13q14
was examined using three markers: D13S263 (located
centromeric to RB1), D13S153 (located within intron 2
of RB1), and RB1 (located within intron 20 of RB1). For
the informative samples, the findings detected by MLPA
were confirmed in all cases (data not shown).
RB1 mutations and response to chemotherapy in vivo
In this study, all breast cancer tissue samples analyzed
(Additional file 1) were obtained from locally advanced
primary breast cancers treated in two prospective trans-
lational phase III studies [20,21], aiming at identifying
markers predicting therapy resistance [22]. All patients
included from both protocols are listed in Additional
file 1 together with their response to therapy. The total
material of 73 tumors included 37 tumors from patients
treated with 5-FU and mitomycin in concert (FUMI);
eight out of these tumors expressed primary therapy
resistance [21]. The remaining 36 patients were selected
from a second study exploring resistance to weekly dox-
orubicin (Dox) among a total of 90 patients [20]. The
sub-cohort analyzed here (n = 36) contained 9 tumors
expressing primary therapy resistance towards
Figure 2 Methylation of the RB1 promoter. RB1 promoter methylation status was analyzed by methylation-specific PCR in 71 patients.
Genomic DNA from patients was bisulfite converted. Figure shows products from MSP and USP of a representative selection of patients. Uctr:
DNA from healthy donor; Mctr: Universally Methylated Control DNA.
Figure 1 Observed RB1 mutations. (a) Schematic representation of the pRb protein. (b) We observed three novel point mutations in RB1: The
C1819A mutation (Leu607Ile), the C1861T mutation (Arg621Cys), and the A2092T mutation (Arg698Trp), all leading to amino acid substitutions
inside the pRb pocket domain.
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having an objective response to or stabilization of dis-
ease during doxorubicin treatment.
Notably, three out of four tumors harboring RB1
mutations (all tumors except the one harboring the
Arg698Trp mutation) expressed primary resistance to
therapy (Table 1 and Additional file 1). Thus, among 68
tumors analyzed by MLPA and cDNA sequencing for
which clinical data on response was available, three out
of a total of 17 tumors resistant to therapy (PD) har-
bored RB1 mutations, contrasting only one out of 51
tumors with stable disease or an objective response (p =
0.046). In contrast, no correlation between RB1 allelic
imbalance and treatment response was found, and
neither mutational status nor AI correlated to overall
survival.
Multiple sequence alignment of the pRb spacer
The two point mutations Leu607Ile and Arg621Cys are
both located in the spacer region, previously assumed to
be non-essential to pRb protein function [23]. Employ-
ing ClustalX using default parameters [24], a multiple
sequence alignment of the pRb spacer region including
sequences from eight different species was constructed.
As shown in Figure 3, the spacer region is fairly well
conserved. In fact, the human and mouse RB1-spacer
sequences have a higher level of identity than the aver-
age human-mouse sequence identity (82% versus 70%).
This finding indicates that the spacer region is of impor-
tant for pRb function.
In silico structural modeling analysis
The Arg698Trp mutation is located in the B box of the
pRb pocket (Figure 4a). In silico structural analysis of
the pRb pocket [23] revealed the Arg698 residue to
form a hydrogen-bond network (Figure 4b) and pre-
dicted Arg698Trp to disrupt this intramolecular
hydrogen bond network with a possible structural and
functional consequence on the pRb protein.
Subcellular localization
Exploring expression of the mutant proteins in trans-
fected RB1-deficient C-33 A cells, immunostaining
revealed positive nuclear staining for all the three pRb
point mutants (Leu607Ile, Arg698Trp, and Arg621Cys)
similar as for pRb wild-type (Figure 5). Each control was
negative with respect to unspecific fluorescence staining.
This indicates that none of the mutants express altered
activity due to improper subcellular localization.
Apoptotic function and stability of the pRb mutant
proteins
In addition to inhibit cell cycle progression, previous
studies of the wild-type pRb protein have revealed pro-
[19,25,26] as well as anti-[14-17] apoptotic functions in
response to among others genotoxic stress like treat-
ment with cytotoxic compounds in vitro.
As two of the three point mutations were observed in
patients not responding to DNA damaging chemother-
apy, we aimed at exploring the ability of the wild-type
and mutant pRb proteins to mediate apoptosis in RB1-
deficient C-33 A cells following treatment with doxoru-
bicin. Analysis by TUNEL assay revealed transfection of
wild-type pRb to restore apoptosis in response to doxor-
ubicin treatment in C-33 A cells (Figure 6a). While each
of the point mutated pRb variants expressed some pro-
apoptotic function, this was significantly reduced as
compared to wild-type protein. Notably, these observa-
tions were confirmed in a second RB1-deficient cell line
(Saos-2; Figure 6b) revealing the reduced pro-apoptotic
effect to occur independent of cell line used (p ≤ 0.01
for all comparisons).
Following plasmid transfection with identical amounts
of DNA, western blot analyses on samples run in
Figure 3 Multiple sequence alignment of the pRb spacer region. A multiple sequence alignment of the spacer region between the A and B
boxes of the pRb pocket was generated with ClustalX using default parameters [24]. The locations of two of the mutations reported here are
marked with black arrows, and two previously reported mutations are shown in grey [32,33]. Sequences from eight different species were
included in the alignment: Human [UNIPROT: P06400 RB_HUMAN], cow [UNIPROT: Q08E68_BOVIN], mouse [UNIPROT: P13405 RB_MOUSE],
chicken [UNIPROT: Q90600 RB_CHICK], newt [UNIPROT: Q98966_NOTVI], salmon [UNIPROT: C0H9R0_SALSA], killifish [UNIPROT: Q5J3Q9_FUNHE],
and zebrafish [UNIPROT: A0JMQ4_DANRE].
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and Arg698Trp mutants to reach lower protein amounts
as compared to wild-type protein and the Arg621Cys
mutant (Figure 6c and 6d). Protein measurement follow-
ing cycloheximide treatment (Figure 7) revealed both
Leu607Ile and Arg698Trp to display reduced stability,
thus explaining the mechanism for reduced protein
levels.
Consistent with the observed apoptotic responses, cell
transformation experiments using NIH 3T3 cells
revealed a slight, but not significant, increase in foci for-
mation in cells transfected with plasmids carrying the
mutant RB1 genes compared to wild-type RB1 (data not
shown).
Discussion
T h ep r e s e n tw o r ki st h ef i r s ts t u d yr e p o r t i n gRB1 point
mutations in primary breast carcinomas. Based on our
findings that all three point mutated pRb proteins
expressed reduced pro-apoptotic effect in vitro,a n d
three out of four tumors harboring RB1 mutations were
resistant to chemotherapy, our data provide the first
indication that RB1 alterations could influence breast
cancer chemosensitivity in vivo.
Somatic point mutations in RB1 have been detected in
different malignancies including bladder [4] and prostate
[5] cancer. While previous studies have examined breast
cancer samples with respect to RB1 LOH, loss of pRb
immunostaining [3] and chromosomal rearrangements
[7], except for one study reporting no mutations when
sequencing the exon 21 only [27] and the finding of
point mutations in a single breast cancer cell line [8],
we are not aware of any study reporting RB1 point
mutations in breast cancer tissue http://rb1-lsdb.d-
lohmann.de/.
In this study, we evaluated potential point mutations
through gene sequencing (N = 73) and intragenetic
deletions by use of MLPA (N = 71) across the whole
coding region of the RB1 gene in stage III breast can-
cers. We identified three novel single nucleotide muta-
tions in RB1, each leading to amino acid substitutions.
While one of the point mutations was germline, the
patient harboring this alteration revealed no family his-
tory of retinoblastoma or family clustering of either
breast cancer or any other malignancy.
Each of the detected point mutations was located in
the functionally important pocket domain. The pocket is
essential for pRb’s interaction with other proteins [28].
It consists of the so-called A and B boxes [23], forming
a tight hydrophobic interface, with the two parts being
covalently linked by the spacer region (Figure 1). Thus,
mutations affecting the A [29] and B [30] boxes of
pocket domain are known to give rise to pRb proteins
with disturbed function. Alterations located in both of
these parts have been detected in human sporadic can-
cers [4,5], but also as germline mutations in patients
with retinoblastoma [31,32]. One of the point mutations
identified here (Arg698Trp) is located in the B box, and
in silico structural analysis suggested this mutation to
disrupt a hydrogen-bond network. Furthermore, our
f i n d i n g si n d i c a t et h i sm u t a n tt ob el e s ss t a b l et h a nt h e
wild-type pRb protein (Figure 7). Taken together, these
findings suggest that mutations in this location might
significantly affect pRb function and stability. In
Figure 4 Structural model of the pRb pocket domain. (a) The cartoon shows the pRb pocket in complex with peptides from the
transcription factor E2F (magenta) and the human papilloma virus protein E7 (yellow). The A and B boxes are colored green and cyan,
respectively. The model was made from two structures: PDB: 1GUX (Rb pocket and E7 peptide) and PDB: 1O9K (E2F peptide). (b) Close-up view
of the arginine 698 (R698) and amino acids that have at least one atom within a 4Å distance to the side chain atoms of R698. The R698 that is
mutated to tryptophan in one of the tumors is located in the B box of the pRb pocket, and forms a hydrogen bond network with three
backbone carbonyls. Hydrogen bonds to backbone carbonyls of residues L694, L743 and I744 are shown by yellow dotted lines. The structures
were visualized using PyMOL http://www.pymol.org.
Berge et al. Molecular Cancer 2010, 9:173
http://www.molecular-cancer.com/content/9/1/173
Page 5 of 13Figure 5 Subcellular localization of pRb mutants. Immunofluorescence staining of RB1-deficient C-33 A cells transfected with the pcDNA3.1/
V5-His-TOPO vector or one of the four plasmids RB1wild-type-V5, RB1Arg621Cys-V5, RB1Leu607Ile-V5, and RB1Arg698Trp-V5. All mutants display
nuclear localization. Left: DAPI, Centre: Anti-V5 (Texas Red), Right: Overlay.
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Page 6 of 13contrast, mutations Leu607Ile and Arg621Cys locate to
t h es p a c e rr e g i o n .W h i l eg e r m l i n e[ 3 1 - 3 3 ]a sw e l la s
somatic [5] mutations within the spacer region have
been identified, many authors have considered this
domain non-essential to peptide-binding activity of the
pRb pocket [23]. Our alignment analysis confirmed the
spacer domain to be well conserved across different spe-
cies (Figure 3), and the Leu607Ile mutant protein was
considerably less stable compared to pRb wild-type
These findings, in addition to our results revealing both
of these mutations, similar to Arg698Trp, to express a
reduced apoptotic function, further indicates a func-
tional role for this region of the pRb pocket.
Considering the intragenic deletions (exon 21-23 and
exon 13-27), these deletions result in truncated proteins
missing half of the B box and both A and B boxes
respectively, most likely abolishing the function of the
pRb pocket in both cases.
The retinoblastoma gene encodes a nuclear phospho-
protein which in its unphosphorylated state binds to
and inactivates E2F1, causing G1-S phase arrest [1].
Potential additional roles, including pro-apoptotic func-
tions of pRb have been suggested [26]. While most stu-
dies have indicated an anti-apoptotic role of pRb [34],
some studies have shown pRb to enhance apoptosis fol-
lowing g-irradation [25] as well as doxorubicin-induced
DNA damage [19] which is more in accordance with its
role as a tumor suppressor. Here we found the apoptotic
response to doxorubicin treatment to be restored by
transfecting the RB1-deficient C-33 A and Saos-2 cell
lines with wild-type pRb, but only to a minor degree
when transfecting the pRb point mutants, supporting a
Figure 6 Mutant pRb proteins display reduced apoptotic function. (a) Diagram shows percentage of apoptotic (TUNEL positive) cells
following doxorubicin treatment of RB1-deficient C-33 A and (b) Saos-2 cells, transfected with vectors expressing the different pRb mutants,
relative to pRb wild-type (100%). For each mutant, a minimum of 1000 cells were counted in each of three independent experiments. Error bars
indicate standard deviations between the three experiments. p-values given are based on analyses of variance (ANOVA) between the individual
mutants and pRb wild-type. All over, each mutants revealed reduced apoptotic function in both cell lines (p ≤ 0.01). (c) Western blot controls for
TUNEL assay. Panels displaying expression of pRb wild-type and mutants with corresponding actin expression (loading control) from
transfections performed in parallel to those used for TUNEL assays in C-33 A and (d) Saos-2.
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cline therapy (Figure 6a and 6b). However, the corre-
sponding protein level controls and subsequent stability
assays showed that the Leu607Ile and Arg698Trp pRb
mutants were less stable than the mutant Arg621Cys
p R ba n dt h ep R bw i l d - t y p ep roteins which harbored
similar protein levels and stabilities. Thus, we believe
the relatively low percentage of apoptotic cells observed
for all the 3 mutants is due to reduced protein stability
in the case of Leu607Ile and Arg698Trp, and due to
impaired ability to induce apoptosis in the case of the
more stable pRb mutant Arg621Cys.
Further, in support of a pro-apoptotic role of the pRb
protein in breast cancer, three out of four tumors harbor-
ing RB1 mutations expressed resistance to doxorubicin or
mitomycin treatment in vivo. The two drugs have similari-
ties with respect to their mechanisms of antitumor actions.
Thus, the in vitro findings on apoptotic response are con-
sistent with our observations on patient drug resistance
in vivo. The fact that one of the tumors (Dox 111 harbor-
ing Arg698Trp) responded to chemotherapy do not refute
such a hypothesis; while we previously reported mutations
affecting TP53 [20,21] to be associated with chemoresis-
tance in vivo, the predictive power was not 100%; indicat-
ing alternative mechanisms may act in concert [35].
Conclusions
In summary, we demonstrate for the first time point
mutations in RB1 among breast cancer tumors. Most
interestingly, these point mutated genes encode pro-
teins expressing reduced pro-apoptotic effect in vitro,
and three out of four tumors harboring RB1 mutations
were resistant to chemotherapy. Chemoresistance
remains the main obstacle to cure breast cancer as
well as most other solid malignancies. Although RB1
mutations were detected in a minority of tumors
revealing chemoresistance in vivo (3/17), our present
findings with respect to specific RB1 mutations affect-
ing apoptotic response to doxorubicin treatment may
point to functional network(s) potentially important
for drug resistance in vivo.T h e s ef i n d i n g sm e r i t
further investigations of factors involved in the RB1
pathway and their role in chemotherapeutic response
in breast cancer.
Methods
Patients
This study included patients from two prospective stu-
dies addressing the potential role of mutations in TP53
and other genes regarding resistance to treatment with
doxorubicin [20] or mitomycin and 5-fluorouracil [21]
in locally advanced breast cancer. Both studies were
approved by the Regional Ethical Committee, and each
patient gave written informed consent to the procedure.
Because these studies were designed to explore causes
of chemoresistance, we focused on comparing tumors
that showed primary drug resistance (progressive disease
within 12 weeks) with the combined group of tumors
Figure 7 Stability of pRb wild-type and mutant proteins. Panels show the protein levels of pRb wild-type and mutants including
corresponding actin levels as loading control. The samples were harvested 0-6 h after addition of cycloheximide (50 ug/ml) to transfected
C-33 A and Saos-2 cells and examined by SDS-PAGE and western blot analyses.
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Thus, for the patients treated with doxorubicin, we ana-
lyzed RB1 mutational status in all nine tumors that were
resistant to therapy together with a randomly selected
subgroup of 27 responding tumors. Regarding the group
of patients treated with mitomycin and 5-fluorouracil,
we analyzed 37 tumors for the presence of RB1 muta-
tions, including eight patients resistant to therapy [21]
and four none evaluable samples. Included were three
patients with locally advanced breast cancer, treated
with mitomycin and 5-FU, not participating in these
studies. Thus, a total of 73 patients were included
(Additional file 1).
Control subjects
Due to the fact that we discovered a novel germline base
substitution C1861T (Arg621Cys) in one breast cancer
patient, we sought to evaluate its frequency in the gen-
eral Norwegian population. Thus, we examined blood
DNA from 231 healthy women recruited from the
national mammographic program into other studies
described elsewhere [37].
RNA Purification
RNA was purified by Trizol (life Technologies, Inc.)
extraction from snap-frozen tissue samples according to
the manufacturer’s instructions. After extraction, the
RNA was dissolved in diethyl pyrocarbonate-treated
double-distilled, deionized H 2O. cDNA was synthesized
by reverse transcription using Superscript II reverse
transcriptase (Invitrogen)
DNA Purification
G e n o m i cD N Aw a sp u r i f i e df r o mt u m o rt i s s u eo rl y m -
phocytes using QIAamp DNA Mini Kit (Qiagen)
according to the manufacturer’s instructions.
Multiplex ligand probe amplification (MLPA)
MLPA analysis of genomic DNA from 71 patients was
performed using the SALSA MLPA RB1 kit (MRC-
Holland, Amsterdam, The Netherlands) according to
the manufacturer’s instructions. In the patient samples,
the peak areas of all MLPA products resulting from
RB1 specific probes were first normalized by the aver-
age of peak areas resulting from control probes specific
for locations other than on chromosomes 13. A ratio
was then calculated where this normalized value was
divided by the corresponding value from a sample con-
sisting of pooled DNA from 10 healthy individuals. A
sample was scored as having a reduced copy number
at a specific location if this ratio was below 0.75, and
as having an increased copy number if the ratio was
above 1.25.
LOH analysis
Samples shown by MLPA analysis to harbor AI at the
RB1 locus were subsequently analyzed by LOH. Three
markers were applied spanning 13q14.1-3: D13S263,
centromeric to RB1, D13S153, and RB1, the two latter
l o c a t e dw i t h i ni n t r o n2a n di n t r o n2 0o ft h eRB1 gene,
respectively. Both D13S263 and D13S153 are microsat-
telite markers; while RB1 is a variable number tandem
repeat (VNTR). All three markers were amplified by
PCR using primers as specified in Table 2 and the PCR
products were analyzed on an automated DNA sequen-
cer (ABI 3700). Data were analyzed by comparing nor-
mal and tumor tissue allele peak-height ratios. A sample
was scored as having AI when the ratio between height
of tumor and normal sample was less than 0.84 [38].
PCR Amplification of RB1 from cDNA
Six fragments encompassing the RB1 reading frame
starting from nucleotide 89 to 2749 (TGA) were ampli-
fied by nested PCR using the primers listed in Table 2.
The nucleotides 1 (starting from ATG) to 88 were not
covered by our analysis. The frequency of published
mutations in this region is approximately 2% for patients
with retinoblastoma http://rb1-lsdb.d-lohmann.de/. It
was therefore concluded that the risk of missing somatic
alterations was acceptably low. Observed mutations
were verified by PCR amplification of the affected exons
from genomic DNA. In some tumors, no cDNA-based
products were detected for parts of the RB1 gene. To
verify the integrity of the RB1 gene in these patients, we
amplified the exons of interest using genomic DNA.
PCR was carried out with Dynazyme EXT DNA poly-
merase (Dynazyme) in a 50 μl solution containing 1×
PCR buffer, 1.5 mM MgCl 2, 0.5 mM of each deoxynu-
cleotide tri-phosphate, 5% DMSO, 0.2 μM of each pri-
mer, and 0.5 μlo fc D N A ,1μlo ff i r s t - r o u n dP C R -
product or ~50 ng genomic DNA was used as template.
The RB1 PCR conditions for the first round of the
nested PCR for fragments one and two were: An initial
5 min denaturation at 94°C, 40 cycles of 30 sec at 94°C,
30 sec at 52.5°C, and 120 sec at 72°C, and a final 7 min
extension at 72°C. The second round of the nested PCR
for fragments one and two was conducted as follows:
An initial 5 min denaturation at 94°C, 40 cycles of 30
sec at 94°C, 30 sec at 55.6°C, and 60 sec at 72°C, and a
final 10 min extension at 72°C.
The RB1 PCR conditions for both rounds of the
nested PCR for fragments three to six were identical
and consisted of: An initial 5 min denaturation at 94°C,
40 cycles of 30 sec at 94°C, 30 sec at 45°C, and 120 sec
at 72°C, and a final 7 min extension at 72°C.
PCR on genomic DNA was done with an initial 5 min
denaturation at 94°C, 40 cycles of 60 sec at 94°C, 30 sec
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Page 9 of 13Table 2 PCR and DNA sequencing primers
Primer name Sense primer Anti sense primer Length
(bp)
Annealing Temp.
(°C)
RB1M 5’-GGG AGT TTC GCG GACGTG AC-3’ 5’-ACGT C GAAA CAC GCC CCG-3’ 172 65.0
RB1U 5’-GGG AGT TTT GTG GAT GTG AT-3’ 5’-ACAT C AAAA CAC ACC CCA-3’ 172 61.0
RB1 promoter 5’-CGC CCC AGT TCC CCA CAG A-3’ 5’-GGC AAC TGA GCG CCG CGT-3’ 163 53.0
RB1 exon 1 5’-AAC GGG AGT CGG GAG AG-3’ 5’-AAT CCT GTC ACC ATT CTG C-3’ 412 55.2
RB1 exon 2 5’-GAT TAT TTT CAT TTG GTA GGC-3’ 5’-AAA GTG GTA GGA TTA CAG GC-3’ 351 51.3
RB1 exon 3 5’-TTT TAA CAT AGT ATC CAG TGT GTG-3’ 5’-TAC ACT TTC ATA ACG GCT CC-3’ 350 54.4
RB1 exon 4 5’-GAC CCT TCG TTT TCT TAT ATT CTC-3’ 5’-ATC AGA GTG TAA CCC TAA TAA AAT
G-3’
390 55.2
RB1 exon 5 5’-ATT GGG AAA ATC TAC TTG AAC-3’ 5’-TCA AAC TAA CCC TAA CTA TCA AG-
3’
265 54.2
RB1 exon 6 5’-CAT TCT ATT ATG CAT TTA ACT AAG G-3’ 5’-CTA ACA GTT AAT AAG CCA AGC AG-
3’
340 53.6
RB1 exon 7 5’-ATG GAT ATA CTC TAC CCT GCG-3’ 5’-ATC CTG TCA GCC TTA GAA CC-3’ 291 55.2
RB1 exon 8 5’-TAA AAG TAG TAG AAT GTT ACC AAG-3’ 5’-CAG TGA TTC CAG AGT GAG G-3’ 470 55.2
RB1 exon 9 5’-TTG ACA CCT CTA ACT TAC CCT G-3’ 5’-TTG GCT AGA TTC TTC TTG GG-3’ 301 55.7
RB1 exon 10 5’-GAA ATC TGT GCC TCT GTG TG-3’ 5’-AAA GGT AAC TGT TAT AGG ACA
CAC-3’
200 52.9
RB1 exon 11 5’-GTT ATC AAT ACC ACC AGG GAG-3’ 5’-CAA ATC TGA AAC ACT ATA AAG CC-
3’
443 53.0
RB1 exon 19 5’-AGA CAA GAT GTA TCT GGG TGT AC-3’ 5’-CAT GAT TTG AAC CCA GTC AG-3’ 306 53.6
RB1 exon 20 5’-CTT ATT CCC ACA GTG TAT GCC-3’ 5’-AGC CTG GGT AAC AGA GTG AG-3’ 341 47.5
RB1 exon 21 5’-ATT CTG ACT ACT TTT ACA TC-3’ 5’-TTA TGT TAT GGA TAT GGA T-3’ 192 58.0
RB1 exon 22.1 5’-ATA TGT GCT TCT TAC CAG T-3’ 5’-CAC GTT TGA ATG TCT GAG GA-3’ 148 53.5
RB1 exon 22.2 5’-CCT CAG ACA TTC AAA CGT GT-3’ 5’-TTG GTG GAC CCA TTA CAT TA-3’ 175 54.1
RB1 exon 23 5’-TAA TGT AAT GGG TCC ACC AA-3’ 5’-TCA AAA TAA TCC CCC TCT CA-3’ 277 55.6
RB1 exon 24 5’-GAA TGA TGT ATT TAT GCT CA-3’ 5’-TTC TTT TAT ACT TAC AAT GC-3’ 165 46.1
RB1 exon 25 5’-CTT TGC CTG ATT TTT GAC AC-3’ 5’-CAG TGC TGA GAC TCT GGA TTC-3’ 270 56.3
RB1 exon 26 5’-CAT TTA TGT TTT AGA TGG TTA G-3’ 5’-GTT TAT TTC GTT TAC ACA AG-3’ 318 46.8
RB1 exon 27 5’-CAG CCA CTT GCC AAC TTA C-3’ 5’-CAT AAA CAG AAC CTG GGA AAG-3’ 230 53.5
RB1-1.r-S2/AS4 5’-AAC GGG AGT CGG GAG AG-3’ 5’-GAA TTA CAT TCA CCT CTT CAT CAA
G-3’
1204 45.0
RB1-1.r-S3/AS2 5’-ATG ATA AAA CTC TTC AGA CTG ATT C-3’ 5’-TGT CCA CCA AGG TCC TGA G-3’ 1794 45.0
RB1-2.r-frag1-S/AS 5’-AGG AGG ACC CAG AGC AGG AC-3’ 5’-CCA AGA AAC TTT TAG CAC CAA TG-
3’
496 45.0
RB1-2.r-frag2-S/AS 5’-CTA CTG AAA TAA ATT CTG CAT TGG T-3’ 5’-CTC TTC ATC AAG GTT ACT TTT TCG
T-3’
528 45.0
RB1-2.r-frag3-S/AS 5’-GAA ACA CAG AGA ACA CCA C-3’ 5’-ATT CTG AGA TGT ACT TCT GCT A-3’ 461 45.0
RB1-2.r-frag4-S/AS 5’-AGC AAA CTT CTG AAT GAC AAC-3’ 5’-GAG AGG TAG ATT TCA ATG G-3’ 518 45.0
RB1-2.r-frag5-S/AS 5’-CTC CAA AGA AAA AAG GTT CAA-3’ 5’-GGT ATT GGT GAC AAG GTA GG-3’ 512 45.0
RB1-2.r-frag6-S/AS 5’-GTA TTC TAT AAC TCG GTC TTC A-3’ 5’-CAT TTC TCT TCC TTG TTT GA-3’ 526 45.0
RB1-plasmid-S1/
AS1
5’-GGT TTT TCT CAG GGG ACG-3’ 5’-GTG AGA GAC AAT GAA TCC AGA G-
3’
45.0
RB1-plasmid-S/AS-
STOP
5’-CAC AGC TCG CTG GCT CCC-3’ 5’-TTT CTC TTC CTT GTT TGA G-3’ 45.0
RB1 (Leu607Ile) 5’-GCA GCA GAT ATG TAT ATT TCT CCT GTA AGA
TCT CC-3’
RB1 (Arg621Cys) 5’-AAA GGT TCA ACT ACG TGT GTA AAT TCT ACT
GC-3’
RB1 (Arg698Trp) 5’-GAA CTC ATG AGA GAC TGG CAT TTG GAC CAA
ATT ATG-3’
D13S153 F/R 5’-TTG CAC TGT GGA GAT AAA CAC ATA G-3’ 5’-TCA CAT TGT CTT TTA AGG CAG
GAG-3’
D13S263 F/R 5’-CCT GGC CTG TTA GTT TTT ATT GTT A-3’ 5’-CCC AGT CTT GGG TAT GTT TTT A-3’
RB1 5’-TGT ATC GGC TAG CCT ATC TC-3’ 5’-AAT TAA CAA GGT GTG GTG G-3’
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(Table 2), and 45 sec at 72°C, and a final 7 min exten-
sion at 72°C.
Finally, the RB1 promoter PCR was done with an
initial 5 min denaturation at 94°C, 35 cycles of 30 sec
at 94°C, 30 sec at 53°C, and 45 sec at 72°C, and a final
5 min extension at 72°C.
DNA Sequencing
Sequencing was performed as described previously [39]
using primers specific for the different RB1 fragments
(Table 2). The sequences generated were compared with
wild-type RB1 (GenBank accession number: L11910) for
sequence alterations.
Promoter Methylation Analysis
RB1 promoter methylation status was analyzed by
methylation-specific PCR in 71 patients. Genomic DNA
from patients was modified using the CpGenome DNA
Modification Kit (Intergen), and primers designed speci-
fic for methylated (RB1M-S and RB1M-AS, Table 2)
and unmethylated (RB1U-S and RB1U-AS, Table 2)
DNA [40]. Methylation- and unmethylation-specific
PCRs (MSP and USP) were done with AmpliTaq Gold
DNA Polymerase (Applied Biosystems) in a 50 μls o l u -
tion containing 1× PCR buffer, 1.5 mM MgCl 2, 0.5 mM
of each deoxynucleotidet r i p h o s p h a t e ,0 . 2μM of each
primer and 25 ng of modified genomic DNA. The
methylation-specific PCR was carried out for 35 cycles
of 60 sec at 95°C, 45 sec at 65°C, and 1 min at 72°C.
The unmethylation-specific PCR was carried out for 35
cycles of 60 sec at 95°C, 45 sec at 61°C, and 1 min at
72°C. Both PCRs were performed with an initial 5 min
of denaturation at 95°C and concluded with 2 min at
72°C. After amplification, the PCR products were visua-
lized on a 3% agarose gel. Included in each run was a
positive control (CpGenome Universal Methylated
DNA, Millipore) and two negative controls (modified
DNA from healthy donors and water).
Plasmid constructs
RB1 wild-type was amplifiedf r o mc D N Ab yn e s t e dP C R
using the primers RB1-plasmid-S1 and RB1-plasmid-AS1
in the first, and RB1-plasmid-S and RB-AS-STOP in the
second PCR (Table 2). The first PCR was carried out in a
50 μl reaction mixture of 2.5 U KOD XL DNA polymer-
ase (Novagen), 1× PCR buffer, 0.2 mM of each deoxynu-
cleotide triphosphate, 0.2 μM of each primer and 10 μlo f
cDNA. The thermal conditions for the first PCR were as
follows: 94°C for 5 min, 30 cycles of 30 sec at 94°C, 2 sec
at 45°C and 180 sec at 70°C and a final extension at 74°C
for 10 min. For the second PCR, a 50 μl reaction solution
was made consisting of 0.5 U Dynazyme EXT DNA poly-
merase, 1× PCR buffer, 5% DMSO, 0.2 mM of each
deoxynucleotide triphosphate, 0.2 μM of each primer and
1 μl of first-round PCR product. The amplification condi-
tions were: 5 min denaturation at 94°C followed by
40 cycles of 30 sec at 94°C, 30 sec at 45°C and 180 sec at
72°C before a final step at 72°C for 7 min.
The final PCR product was TA-cloned into the
expression vector pcDNA3.1/V5-His TOPO (Invitrogen)
according to the manufacturer’s instructions. Using the
resulting construct RB1wild-type-V5, corresponding pri-
mers (Table 2), and QuickChange Multi Site-Directed
Mutagenesis Kit (Stratagene), the following constructs
were made; RB1Arg621Cys-V5, RB1Leu607Ile-V5, and
RB1Arg698Trp-V5.
Cell culture and transfection
C-33 A cells and Saos-2 cells were cultured in EMEM
and McCoys 5A, respectively, supplemented with 10%
FBS. Both cell lines were purchased from ATCC (Amer-
ican Type Culture Collection). Transfection was per-
formed using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instruction.
Western blot analysis
Protein samples were separated on 8% SDS-polyacryla-
mide gels and blotted onto nitrocellulose membranes
(Whatman). The membranes were probed with the fol-
lowing antibodies: anti-V5 (Invitrogen) and anti-actin
(Santa Cruz Biotechnology), and the HRP-conjugated 2.
antibodies sheep anti-mouse (GE Healthcare) and
mouse anti-goat (Santa Cruz Biotechnology). Signals
were detected using ECL Western blotting Detection
Reagents (GE Healthcare).
Protein stability
Analyses of protein stability using cycloheximide was
performed as previously described [41]. After 0, 2, 4,
a n d6h ,t h ec e l l sw e r eh a r v e s t e da n dl y s e di n1XS D S
lysis buffer (0.075 M Tris pH 6.8, 2% SDS, 20% glycerol,
0.1 M b-mercaptoethanol, 0.01% bromphenol blue). The
samples were analyzed by SDS-PAGE and western blot
using anti-V5 and anti-actin (loading control).
Immunofluorescence
Cells grown on cover slips were fixed in 3.7% formalde-
hyde for 20 minutes and washed with 1× PBS. The cells
were permeabilized for 12 minutes using 0.1% triton
X100 in 1× PBS before blocking with 1% BSA in 1×
PBS. Detection of the corresponding proteins was per-
formed using monoclonal mouse anti-V5 and TXR-
conjugated goat anti-mouse Ig secondary antibody. The
slides were mounted with Vectashield (Vector Labora-
tories, USA) and examined using a confocal laser scan-
ning microscope (Leica TCS Confocal System attached
to a Leica DM RXA microscope).
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Page 11 of 13Statistical Analysis
Alterations in the RB1 gene were correlated to
response to chemotherapy by use of Fisher exact test
(p-value given as cumulative, two-sided). Differences
between pRb wild-type and mutants with respect to
induction of apoptosis were evaluated by analyses of
variance (ANOVA). Subject to statistical significance,
the efficacy of each mutant was compared to pRb
wild-type with use of the Student test for 2 samples.
Statistical calculations were performed using the SPSS
15.0 software and http://www.quantitativeskills.com/
sisa/.
TUNEL assay
RB1-deficient C-33 A cells [26] were transfected with
pcDNA3.1/V5-His-TOPO vector or one of the four con-
structs RB1wild-type-V5, RB1Arg621Cys-V5,
RB1Leu607Ile-V5, or RB1Arg698Trp-V5. After 24 hours,
the cells were treated with 5 μM doxorubicin (adriamy-
cin) for 6 hours, and washed with 1× PBS before cytos-
pins were prepared. The cells were fixed with 3.7%
paraformaldehyde o.n at room temperature and perm-
abilized with 0.1% Triton X-100 in sodium citrate for 2
min on ice. TUNEL reaction mixture (In situ Cell Death
Detection Kit, TMR red, Roche) was applied for 2.5 h in
dark at 37°C. Controls were either treated with DNaseI
(positive control) or with a TUNEL reaction mixture
not containing enzyme. Hoechst was used to visualize
the nucleus and the cells were analyzed using Leica
DMI6000B epifluorescence microscope (Leica Microsys-
tems). A minimum of 1000 cells for all samples were
counted in each of three independent experiments. The
same experiment was repeated in Saos-2 cells. Here, the
optimal conditions for detection of changes in pro-apop-
totic function differed from C-33 A cells. Saos-2 cells
were treated with 0.5 μM doxorubicin (adriamycin) for
12 hours before harvest.
Additional material
Additional file 1: Characteristics of all patients included in the
study. Treatment, age, grade, stage of disease, clinical response and
outcome of patients included in the study.
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